BRPI0511988A - potencializador de efeito antitumoral, preparação antitumoral, e método para tratar cáncer - Google Patents
potencializador de efeito antitumoral, preparação antitumoral, e método para tratar cáncerInfo
- Publication number
- BRPI0511988A BRPI0511988A BRPI0511988-0A BRPI0511988A BRPI0511988A BR PI0511988 A BRPI0511988 A BR PI0511988A BR PI0511988 A BRPI0511988 A BR PI0511988A BR PI0511988 A BRPI0511988 A BR PI0511988A
- Authority
- BR
- Brazil
- Prior art keywords
- antitumor
- preparation
- effect
- antitumor effect
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
POTENCIALIZADOR DE EFEITO ANTITUMORAL, PREPARAçãO ANTITUMORAL, E MéTODO PARA TRATAR CáNCER. A presente invenção refere-se um potencializador de efeito antitumoral, um método para tratar câncer, usando uma pluralidade de preparações farmacêuticas que têm excelente atividade antitumoral, e uma preparação antitumoral. Particularmente, a presente invenção fornece um potencializador de efeito antitumoral, para potencializar a atividade antitumoral de uma preparação antitumoral que compreende tegafur em uma quantidade terapeuticamente eficaz, gimeracil em uma quantidade eficaz para potencializar um efeito antitumoral, e oteracil potássica em uma quantidade eficaz para inibir um efeito colateral, sendo que o potencializador de efeito antitumoral compreende cis-oxalato de (1R,2R-diamino-ciclohexano)-platina(II) em uma quantidade eficaz para potencializar um efeito antitumoral; um método para tratar câncer que compreende a etapa de administrar concomitantemente tegafur em uma quantidade terapeuticamente eficaz, gimeracil em uma quantidade eficaz para potencializar um efeito antitumoral, e oteracil potássica em uma quantidade eficaz para inibir um efeito colateral, sendo que o potencializador de efeito antitumoral compreende cis-oxalato de (1R,2R- diamino-ciclohexano)-platifla(II) em uma quantidade eficaz para potencializar um efeito antitumoral; uma preparação antitumoral em uma forma farmacêutica que compreende uma pluralidade de agentes farmacêuticos, cada um dos quais contendo um dos ingredientes ativos que consistem em tegafur, gimeracil, oteracil potássica, e cis-oxalato de (1R,2R-diamino-ciclohexano)- platina(II), ou cada um dos quais contendo tais ingredientes ativos em qualquer combinação, ou em uma forma farmacêutica que compreende um único agente farmacêutico que contém todos os ingredientes ativos; e um kit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004171520 | 2004-06-09 | ||
| PCT/JP2005/010182 WO2005120480A1 (ja) | 2004-06-09 | 2005-06-02 | 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511988A true BRPI0511988A (pt) | 2008-01-22 |
Family
ID=35502806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511988-0A BRPI0511988A (pt) | 2004-06-09 | 2005-06-02 | potencializador de efeito antitumoral, preparação antitumoral, e método para tratar cáncer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20080306073A1 (pt) |
| EP (1) | EP1757283B1 (pt) |
| JP (1) | JP5578753B2 (pt) |
| CN (2) | CN1964707A (pt) |
| AU (1) | AU2005251588B2 (pt) |
| BR (1) | BRPI0511988A (pt) |
| CA (1) | CA2569739C (pt) |
| CY (1) | CY1113509T1 (pt) |
| DK (1) | DK1757283T3 (pt) |
| EA (1) | EA011573B1 (pt) |
| ES (1) | ES2393398T3 (pt) |
| HR (1) | HRP20121062T1 (pt) |
| IL (1) | IL179885A (pt) |
| ME (1) | ME01460B (pt) |
| MX (1) | MXPA06014477A (pt) |
| MY (1) | MY140563A (pt) |
| NO (1) | NO20070136L (pt) |
| NZ (1) | NZ551637A (pt) |
| PL (1) | PL1757283T3 (pt) |
| PT (1) | PT1757283E (pt) |
| RS (1) | RS52668B (pt) |
| SI (1) | SI1757283T1 (pt) |
| TW (1) | TWI324929B (pt) |
| WO (1) | WO2005120480A1 (pt) |
| ZA (1) | ZA200700134B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101503559B1 (ko) * | 2007-12-27 | 2015-03-17 | 다이호야쿠힌고교 가부시키가이샤 | 경구 분립상 항종양제 |
| TWI468188B (zh) * | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
| WO2009139085A1 (ja) * | 2008-05-12 | 2009-11-19 | 静岡県 | 抗腫瘍剤、キット及び癌治療方法 |
| JP5553522B2 (ja) * | 2009-03-31 | 2014-07-16 | 大鵬薬品工業株式会社 | 経口投与用医薬組成物 |
| CN102309492A (zh) * | 2010-07-02 | 2012-01-11 | 天津金耀集团有限公司 | 一种替加氟、吉美斯特和奥替拉西钾复方注射液 |
| KR20140144213A (ko) | 2012-03-16 | 2014-12-18 | 다이호야쿠힌고교 가부시키가이샤 | 3제를 조합한 신규 항종양제 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996004904A1 (fr) * | 1994-08-08 | 1996-02-22 | Debiopharm S.A. | Preparation pharmaceutiquement stable d'oxaliplatine |
| AU2001240001A1 (en) * | 2000-03-08 | 2001-09-17 | Bristol-Myers Squibb Company | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| CA2457148A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
| US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
-
2005
- 2005-06-02 ZA ZA200700134A patent/ZA200700134B/en unknown
- 2005-06-02 JP JP2006514477A patent/JP5578753B2/ja not_active Expired - Fee Related
- 2005-06-02 WO PCT/JP2005/010182 patent/WO2005120480A1/ja active Application Filing
- 2005-06-02 EP EP05745983A patent/EP1757283B1/en active Active
- 2005-06-02 RS RS20120582A patent/RS52668B/en unknown
- 2005-06-02 ME MEP-2013-2A patent/ME01460B/me unknown
- 2005-06-02 BR BRPI0511988-0A patent/BRPI0511988A/pt not_active Application Discontinuation
- 2005-06-02 MX MXPA06014477A patent/MXPA06014477A/es active IP Right Grant
- 2005-06-02 CN CNA2005800189099A patent/CN1964707A/zh active Pending
- 2005-06-02 ES ES05745983T patent/ES2393398T3/es active Active
- 2005-06-02 DK DK05745983.6T patent/DK1757283T3/da active
- 2005-06-02 SI SI200531637T patent/SI1757283T1/sl unknown
- 2005-06-02 NZ NZ551637A patent/NZ551637A/en unknown
- 2005-06-02 US US11/629,185 patent/US20080306073A1/en not_active Abandoned
- 2005-06-02 CA CA2569739A patent/CA2569739C/en not_active Expired - Fee Related
- 2005-06-02 CN CN2012104510733A patent/CN103054871A/zh active Pending
- 2005-06-02 AU AU2005251588A patent/AU2005251588B2/en not_active Ceased
- 2005-06-02 EA EA200602282A patent/EA011573B1/ru not_active IP Right Cessation
- 2005-06-02 PL PL05745983T patent/PL1757283T3/pl unknown
- 2005-06-02 PT PT57459836T patent/PT1757283E/pt unknown
- 2005-06-08 TW TW094118875A patent/TWI324929B/zh active
- 2005-06-09 MY MYPI20052620A patent/MY140563A/en unknown
-
2006
- 2006-12-06 IL IL179885A patent/IL179885A/en active IP Right Grant
-
2007
- 2007-01-08 NO NO20070136A patent/NO20070136L/no not_active Application Discontinuation
-
2012
- 2012-12-21 HR HRP20121062TT patent/HRP20121062T1/hr unknown
-
2013
- 2013-01-04 CY CY20131100005T patent/CY1113509T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ551637A (en) | 2010-05-28 |
| EP1757283A4 (en) | 2009-09-02 |
| CN1964707A (zh) | 2007-05-16 |
| CA2569739A1 (en) | 2005-12-22 |
| EP1757283A1 (en) | 2007-02-28 |
| MXPA06014477A (es) | 2007-03-21 |
| NO20070136L (no) | 2007-02-09 |
| JPWO2005120480A1 (ja) | 2008-04-03 |
| EA011573B1 (ru) | 2009-04-28 |
| DK1757283T3 (da) | 2012-11-12 |
| WO2005120480A1 (ja) | 2005-12-22 |
| HRP20121062T1 (hr) | 2013-01-31 |
| ES2393398T3 (es) | 2012-12-21 |
| CN103054871A (zh) | 2013-04-24 |
| EP1757283B1 (en) | 2012-10-17 |
| US20080306073A1 (en) | 2008-12-11 |
| TWI324929B (en) | 2010-05-21 |
| IL179885A (en) | 2011-08-31 |
| SI1757283T1 (sl) | 2013-01-31 |
| CY1113509T1 (el) | 2016-06-22 |
| PL1757283T3 (pl) | 2013-03-29 |
| EA200602282A1 (ru) | 2007-04-27 |
| MY140563A (en) | 2009-12-31 |
| RS52668B (en) | 2013-06-28 |
| CA2569739C (en) | 2011-11-29 |
| IL179885A0 (en) | 2007-05-15 |
| JP5578753B2 (ja) | 2014-08-27 |
| TW200603809A (en) | 2006-02-01 |
| ME01460B (me) | 2014-04-20 |
| AU2005251588A1 (en) | 2005-12-22 |
| PT1757283E (pt) | 2012-12-07 |
| ZA200700134B (en) | 2008-05-28 |
| AU2005251588B2 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511988A (pt) | potencializador de efeito antitumoral, preparação antitumoral, e método para tratar cáncer | |
| EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
| MY141119A (en) | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | |
| NO20061925L (no) | Farmasoytiske preparater for forebyggelse av overdose eller misbruk | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| DE59911734D1 (de) | Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c | |
| NO20064753L (no) | Kombinasjonsterapi | |
| TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
| DK1383516T3 (da) | Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| AR022462A1 (es) | Uso de un agente que disminuye el colesterol | |
| DE50212933D1 (de) | Die verwendung von pyrimidinnukleosiden und/oder prodrugs davon zur bekämpfung von nebenwirkungen der "haart" (highly active anti-retroviral therapy) und anderen antiviralen therapien | |
| DE60321175D1 (de) | Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten | |
| DE502004002561D1 (de) | Pharmazeutische kombinationspräparate zur krebstherapie enthaltend glutaminase und antineoplastische anthracycline oder platinverbindungen | |
| WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
| TH84859B (th) | ตัวเสริมผลต้านเนื้องอก, ส่วนเตรียมต้านเนื้องอก และวิธีสำหรับการรักษามะเร็ง | |
| DK1572715T3 (da) | Steroidforbindelser med antitumor-aktivitet | |
| AU2003266031A1 (en) | Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours | |
| BR0312283A (pt) | Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf | |
| UA94033C2 (en) | Use of pde3 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE N?O FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |